Pain Therapeutics Inc.

News & Analysis

pain therapeutics inc. - All News and Analysis

• Thursday Options Outlook: LEH, MER, GE, PTIE, AMLN, UNH, DBA

  Seeking Alpha - 2008-09-11

  Rebecca Engmann Darst co-authored this article. Lehman Brothers LEH – Caught at the very center of this Jupiter’s storm in volatility is, of course, Lehman Brothers, whose fight for survival has incited so much of the sector’s turbulence in recent sessions. Shares have taken back some early losses after struggling...

  Tags: General Electric Co., US Market, Amylin Pharmaceuticals Inc., Lehman Brothers Holdings Inc., Merrill Lynch & Co. Inc., Pain Therapeutics Inc., UnitedHealth Group Inc.

Additional Resources

• NeurAxon, Inc. to Present at the BIO National Venture Conference April 1, 2009

  - 2009-03-27

  WALTHAM, Mass. -- NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present at the BIO National Venture Conference taking...

• Research and Markets: The Global Pain Therapeutics Market, 3rd Edition - Market Analysis, R&D Pipelines and Competitive Landscape

  - 2009-03-19

  DUBLIN, Ireland -- Research and Markets ( http://www.researchandmarkets.com/research/bf38da/the_global_pain_th ) has announced the addition of the "The Global Pain Therapeutics Market, 3rd Edition - Market Analysis, R&D Pipelines and...

• Research and Markets: Recently Updated Reports Reveals the Fundamentals of Pain Therapeutics and Examines the Latest Drugs, Markets and Companies

  - 2009-02-11

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/edfb6a/pain_therapeutics) has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering. This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain....

• Pain Therapeutics Inc

  - 2008-12-15

  Pain Therapeutics Inc. Nasdaq fell $1.96, or 24%, to $6.38 and King Pharmaceuticals Inc. NYSE slid 21 cents, or 2%, to $9.45 after FDA staff said they needed more data before approving Remoxy, one of the first painkillers designed to prevent abuse. The FDA "believes additional non-clinical data will be...

• Zacks Analyst Blog Highlights: Pain Therapeutics Inc., Animal Health International, Inc., Companhia Paranaense de Energia, Internap Network Services Corp. and Buckeye Partners, L.P

  - 2008-11-18

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pain Therapeutics Inc. (Nasdaq: PTIE), Animal Health International, Inc. (Nasdaq: AHII),...

• NeurAxon, Inc. to Present at 20th Annual Piper Jaffray Health Care Conference December 2, 2008

  - 2008-11-18

  WALTHAM, Mass. -- NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company's Chief Executive Officer, will present at the 20th Annual Piper Jaffray Health Care Conference taking place December 2-3, 2008 in New York, NY. The NeurAxon presentation will be delivered on Tuesday, December...

• Zacks Bull and Bear of the Day Highlights: SINA Corp., Pain Therapeutics, VeriSign, Commerce Bancshares and Buckeye Partners

  - 2008-11-17

  CHICAGO -- Zacks Equity Research highlights SINA Corporation (Nasdaq: SINA) as the Bull of the Day and Pain Therapeutics, Inc. (Nasdaq: PTIE) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on VeriSign, Inc. (Nasdaq: VRSN), Commerce Bancshares Inc. (Nasdaq: CBSH) and Buckeye Partners, L.P. (NYSE:...

• High Growth Forecasted for The Global Pain Therapeutics Market, 3rd Edition

  - 2008-11-04

  NEW YORK -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. The Global Pain Therapeutics Market, 3rd Edition http://www.reportlinker.com/p096743/The-Global-Pain-Therapeutics- Market-3rd-Edition.html (Due to its length, this URL may need to be copied/pasted into your...

• NeurAxon's NXN-188 Named One of 10 Most Promising Neuroscience Projects by Windhover

  - 2008-10-27

  - NeurAxon to Present at Windhover's Therapeutic Area Partnerships Conference on November 4th- WALTHAM, Mass. -- NeurAxon, Inc., a developer of next-generation pain therapeutics targeting neuronal nitric oxide synthase nNOS, today announced that NXN-188, a novel oral selective nitric oxide synthase inhibitor and 5HT agonist in development for...